Macrolide-Resistant Mycoplasma pneumoniae, United States1
Xiaotian Zheng

, Stella Lee, Rangaraj Selvarangan, Xuan Qin, Yi-Wei Tang, Jeffrey Stiles, Tao Hong, Kathleen Todd, Amy E. Ratliff, Donna M. Crabb, Li Xiao, T. Prescott Atkinson, and Ken B. Waites
Author affiliations: Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA (X. Zheng, S. Lee, K. Todd); The Children's Mercy Hospitals and Clinics, Kansas City, Missouri, USA (R. Selvarangan); Seattle Children’s Hospital, Seattle, Washington, USA (X. Qin); Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, New York, USA (Y.W. Tang, J. Stiles); Hackensack University Medical Center, Hackensack, New Jersey, USA (T. Hong); University of Alabama at Birmingham, Birmingham, Alabama, USA (A.E. Ratliff, D.M. Crabb, L. Xiao, T.P. Atkinson, K.B. Waites)
Main Article
Table
Macrolide-resistant Mycoplasma pneumoniae–positive respiratory specimens, selected US sites, August 2012–April 2014
Collection site |
Specimens
|
No. tested |
No. (%) macrolide resistant |
Chicago, IL |
23 |
4 (17.4) |
Kansas City, MO |
40 |
3 (7.5) |
Hackensack, NJ |
2 |
1 (50.0) |
New York, NY |
5 |
2 (40.0) |
Seattle, WA |
15 |
1 (6.7) |
Birmingham, AL |
6 |
1 (16.7) |
All |
91 |
12 (13.2) |
Main Article
Page created: July 15, 2015
Page updated: July 15, 2015
Page reviewed: July 15, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.